A- A A+

Opioid Use Disorder Induces Oxidative Stress and Inflammation: The Attenuating Effect of Methadone Maintenance Treatment.

Salarian A, Kadkhodaee M, Zahmatkesh M, Seifi B, Bakhshi E, Akhondzadeh S, Adeli S, Askari H, Arbabi M.

Iran J Psychiatry. 2018 Jan;13(1):46-54.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5994232/

Relationship between Serum Methadone Concentration and Cold Pressor Pain Sensitivity in Patients Undergoing Methadone Maintenance Therapy.

Zahari Z, Lee CS, Ibrahim MA, Musa N, Mohd Yasin MA, Lee YY, Tan SC, Mohamad N, Ismail R.

Iran J Pharm Res. 2018 Winter;17(Suppl):8-16.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5958320/

Methadone Concentrations in Exhaled Breath Condensate, Serum and Urine of Patients Under Maintenance Treatment.

Khoubnasabjafari M, Ansarin K, Jouyban-Gharamaleki V, Panahi-Azar V, Hamidi S, Azarmir Z, Jouyban A.

Iran J Pharm Res. 2017 Fall;16(4):1621-1630.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5843324/

Effects of Methadone on Corrected Q-T Interval Prolongation in Critically Ill Children.

Heath TS, Greenberg RG, Hupp SR, Turner DA, Hornik CP, Zimmerman KO.

J Pediatr Pharmacol Ther. 2018 Mar-Apr;23(2):119-124. doi: 10.5863/1551-6776-23.2.119.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5916439/

Methadone treatment, severe food insecurity, and HIV-HCV co-infection: A propensity score matching analysis.

McLinden T, Moodie EEM, Hamelin AM, Harper S, Rossi C, Walmsley SL, Rourke SB, Cooper C, Klein MB, Cox J.

Drug Alcohol Depend. 2018 Feb 20;185:374-380. doi: 10.1016/j.drugalcdep.2017.12.031.

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/29544189

The impact of OPRM1's genetic polymorphisms on methadone maintenance treatment in opioid addicts: a systematic review.

Oueslati B, Moula O, Ghachem R.

Pharmacogenomics. 2018 Jun 1;19(8):741-747. doi: 10.2217/pgs-2018-0017.

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/29785888

Practical Pharmacology of Methadone: A Long-acting Opioid.

Sunilkumar MM, Lockman K.

Indian J Palliat Care. 2018 Jan;24(Suppl 1):S10-S14. doi: 10.4103/IJPC.IJPC_180_17. Review.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5806300/

USA. Methadone Appears Safe and Effective in Treating Fentanyl Addiction: Study

Methadone appears safe and effective in treating people who use fentanyl, suggests a study presented at the recent annual meeting of the American Society of Addiction Medicine. (drugfree.org, 17.05.2018)

https://drugfree.org/learn/drug-and-alcohol-news/featured-news-methadone-appears-safe-effective-treating-fentanyl-addiction-study/

Umstellung von Methadon / Polamidon auf Buprenorphin – die Ravensburger Strategie

Dr.med. Frank Matschinski; SchwerPunktPraxis Ravensburg, 2013

https://www.forum-substitutionspraxis.de/images/Download/PDF/Umstellung_von_Methadon___Polamidon_auf_Buprenorphin__die_Ravensburger_Strategie.pdf

Educational and Behavioral Counseling in a Methadone Maintenance Treatment Program in China: A Randomized Controlled Trial.

Liu P, Song R, Zhang Y, Liu C, Cai B, Liu X, Li J, Chen X, Ke J, Lou J, Chen W, Zhu B, Zou L, Yang Y, Zhu Y, Gong Y, Zhong R, Miao X.

Front Psychiatry. 2018 Apr 4;9:113. doi: 10.3389/fpsyt.2018.00113. eCollection 2018.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5893781/

Respiratory Variability during Sleep in Methadone Maintenance Treatment Patients.

Nguyen CD, Kim JW, Grunstein RR, Thamrin C, Wang D.

J Clin Sleep Med. 2016 Apr 15;12(4):607-16. doi: 10.5664/jcsm.5702.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4795289/

The long-term outcome of patients with heroin use disorder/dual disorder (chronic psychosis) after admission to enhanced methadone maintenance.

Maremmani AGI, Pallucchini A, Rovai L, Bacciardi S, Spera V, Maiello M, Perugi G, Maremmani I.

Ann Gen Psychiatry. 2018 Apr 18;17:14. doi: 10.1186/s12991-018-0185-3. eCollection 2018.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5905164/

Distribution of Methadone and Metabolites in Skeletal Tissue.

Vandenbosch M, Somers T, Cuypers E.

J Anal Toxicol. 2018 Feb 27. doi: 10.1093/jat/bky014.

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/29490025

Primary Care Physicians' Views about Prescribing Methadone to Treat Opioid Use Disorder,

James D. Livingston, Erica Adams, Marlee Jordan, Zachary MacMillan & Ramm Hering (2017)

Substance Use & Misuse, 53:2, 344-353, DOI: 10.1080/10826084.2017.1325376

Abstract

https://www.tandfonline.com/doi/abs/10.1080/10826084.2017.1325376

Methadone Dose Adjustments, Plasma R-Methadone Levels and Therapeutic Outcome of Heroin Users: A Randomized Clinical Trial.

Mannaioni G, Lanzi C, Lotti M, Galli V, Totti A, Pacileo I, Sili M, Pracucci C, Dilaghi A, Bertieri L, Quaranta M, Orsini F, Occupati B, Michahelles A, Ciuti R, Bianchini E, Fabbro G, Biggeri A, Masini E, Moroni F.

Eur Addict Res. 2018 Jan 31;24(1):9-18. doi: 10.1159/000485029.

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/29393208

Effectiveness of Mindfulness-Based Relapse Prevention with Treatment as Usual on Impulsivity and Relapse for Methadone-Treated Patients: A Randomized Clinical Trial.

Yaghubi M, Zargar F, Akbari H. Comparing

Addiction & Health. 2017;9(3):156-165.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5894795/

Effects of Cytochrome P450 Single Nucleotide Polymorphisms on Methadone Metabolism and Pharmacodynamics.

Ahmad T, Valentovic MA, Rankin GO.

Biochem Pharmacol. 2018 Feb 16. pii: S0006-2952(18)30077-7. doi: 10.1016/j.bcp.2018.02.020.

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/29458047

Effectiveness of Transactional Analysis Group Therapy on Addiction Intensity of Woman Patients Treated with Methadone.

Etemadi-Chardah N, Matinpour B, Heshmati R.

Addict Health. 2017 Jul;9(3):146-155.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5894794/

Pharmacogenetics of Methadone Response.

Fonseca F, Torrens M.

Mol Diagn Ther. 2018 Feb;22(1):57-78. doi: 10.1007/s40291-017-0311-y. Review.

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/29168075

Dissatisfaction with opioid maintenance treatment partly explains reported side effects of medications.

Muller AE, Bjørnestad R, Clausen T.

Drug Alcohol Depend. 2018 Mar 29;187:22-28. doi: 10.1016/j.drugalcdep.2018.02.018.

Abstract

https://linkinghub.elsevier.com/retrieve/pii/S0376-8716(18)30165-0

A two-week pilot study of intranasal oxytocin for cocaine-dependent individuals receiving methadone maintenance treatment for opioid use disorder.

Stauffer CS, Musinipally V, Suen A, Lynch KL, Shapiro B, Woolley JD.

Addict Res Theory. 2016;24(6):490-498. doi: 10.3109/16066359.2016.1173682.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5424696/

Methadone Treatment of Opiate Addiction: A Systematic Review of Comparative Studies.

Ali S, Tahir B, Jabeen S, Malik M.

Innov Clin Neurosci. 2017 Aug 1;14(7-8):8-19. eCollection 2017 Jul-Aug. Review.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5880371/

Cardiovascular effects of methadone and concomitant use of diazepam during methadone maintenance treatment induction: low concentration risk.

Mijatović V, Samojlik I, Petković S, Vukmirović S, Uvelin A, Dickov A.

Expert Opin Drug Saf. 2017 Dec;16(12):1323-1328. doi: 10.1080/14740338.2017.1382470.

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/28934555

The OPTIMA study, buprenorphine/naloxone and methadone models of care for the treatment of prescription opioid use disorder: Study design and rationale.

Socias ME, Ahamad K, Le Foll B, Lim R, Bruneau J, Fischer B, Wild TC, Wood E, Jutras-Aswad D.

Contemp Clin Trials. 2018 Apr 5;69:21-27. doi: 10.1016/j.cct.2018.04.001.

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/29627621

The Impact of Enrolment in Methadone Maintenance Therapy on Initiation of Heavy Drinking among People Who Use Heroin.

Klimas J, Wood E, Nguyen P, Dong H, Milloy MJ, Kerr T, Hayashi K.

Eur Addict Res. 2016;22(4):210-4. doi: 10.1159/000444513.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4862898/

*(Levo-) Methadon (Stoffgruppe: Opioid-Analgetikum)

Vor dem Einsatz von (Levo-)Methadon zur Behandlung starker Schmerzen sollte man sich gut mit dessen Pharmakologie und Pharmakokinetik auseinandersetzen. (Levo-)Methadon sollte Patienten, die nicht gut auf Morphin oder andere m-Opioid-Rezeptor-Agonisten ansprechen, vorbehalten sein. Die wichtigsten Fakten dieses Arzneistoffes umfassen:

- sehr variable Plasmahalbwertzeit

- weitaus kompliziertere Dosierung als bei anderen starken Opioiden

- klinisch relevante Veränderungen des Metabolismus durch andere palliativmedizinisch relevante Arzneistoffe

- Zusammenhang mit möglicherweise tödlich verlaufenden Herzrhythmusstörungen (siehe unter Warnhinweise und unter Verlängerung der QT-Zeit in der Palliativmedizin)

- Hinzukommt, dass Methadon aufgrund des Einsatzes in der Substitutionsbehandlung Drogenabhängiger ein soziales Stigma anhaftet. (palliativedrugs.com, Anmeldung nötig, zuletzt aufgerufen 14.04.2018)

https://www.palliativedrugs.com/formulary/de/levo-methadon.html